Truscreen Group Limited’s (ASX:TRU) TruScreen technology has been endorsed in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.
This is considered one of the most important specialist medical clinical guidelines governing management of cervical cancer.
CSCCP’s decision to include TruScreen technology in its new Guideline emphasises the role of new technology in a booming Chinese healthcare sector. The decision is based on the body of evidence supporting TruScreen clinical use world-wide and after extensive consultations with healthcare practitioners and decision makers.
CSCCP is a member of IFCPC (The International Federation of Cervical Pathology and Colposcopy) which is dedicated to reducing the burden of cervical cancer worldwide. The guideline issued by CSCCP is a leading clinical standard for doctors and other healthcare providers as well as government bodies.
This important decision by the CSCCP paves the way for the case of effective screening technologies, such as TruScreen, in the drive to eradicate cervical cancer,” CEO, Dr Beata Edling, said.
“The recent release of the Blue Paper and the CSCCP’s national guideline further validate the use of Artificial Intelligence enabled technology for cervical cancer screening.”